Qure.ai is strategically focusing on partnerships with Indian central and state governments to expand its AI-driven diagnostic tools, particularly for tuberculosis (TB). Despite generating less than 5% of its revenue from India, CEO Prashant Warier highlights a significant opportunity in the public health sector, especially given that India accounted for 25% of global TB cases in 2024, as reported by WHO. The company’s goal is to pilot TB solutions in government hospitals, capitalizing on India’s disproportionate TB burden.
With successful partnerships established in states like Goa, Karnataka, and Punjab, Qure.ai aims to deploy its AI technology across numerous hospitals, enhancing reach significantly. While Qure.ai currently derives most revenue from international markets, including the US and Europe, it targets increased engagement in Europe and is considering acquisitions for expansion. Financially, the company reported a 24.5% revenue growth while addressing costs, anticipating profitability within the next few years as government contracts gain traction.
Source link
